Family planning programs that provide contraceptive services, counseling, and STD testing may be threatened if public funding does not increase and conservative lawmakers have their way, warns The Alan Guttmacher Institute. The nonprofit organization notes that almost 17 million women nationwide rely on the funds provided by Medicaid, Title X of the Public Health Service Act, and state programs to subsidize these family planning services.
Family planning programs that provide contraceptive services, counseling, and STD testing may be threatened if public funding does not increase and conservative lawmakers have their way, warns The Alan Guttmacher Institute. The nonprofit organization notes that almost 17 million women nationwide rely on the funds provided by Medicaid, Title X of the Public Health Service Act, and state programs to subsidize these family planning services.
In the nonprofit organization's analysis, "Conservatives' Agenda Threatens Public Funding for Family Planning," the authors noted that, with more Republicans in Congress, funding for these programs are under attack. In February, for example, President Bush presented a bill to Congress that would cut Medicaid as a whole and change its rules to allow states to reduce some benefits to enrollees, such as possibly getting rid of the guarantee to provide family planning services at no cost.
Moreover, conservatives-concerned that public monies are funding abortion services-are taking aim at these programs. The controversy has caused at least one state, Missouri, to stop funding contraceptive services entirely. Last year, eight states introduced similar legislation.
The institute also emphasized that, despite increasing opposition, these programs are beneficial. It estimates that, for every $1 spent on contraceptive services, $3 is saved on pregnancy-related and newborn care. It also cited a federally commissioned study of Medicaid family planning expansions, which showed that the programs improved access to care, while reducing costs.
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More